{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:15:11Z","timestamp":1758935711786},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.leukres.2008.12.012","type":"journal-article","created":{"date-parts":[[2009,1,31]],"date-time":"2009-01-31T09:46:52Z","timestamp":1233395212000},"page":"902-907","source":"Crossref","is-referenced-by-count":7,"title":["Level of DNA topoisomerase II\u03b1 mRNA predicts the treatment response of relapsed acute leukemic patients"],"prefix":"10.1016","volume":"33","author":[{"given":"Yan-Hua","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoko","family":"Takanashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazue","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norina","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Shiseki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiko","family":"Motoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2008.12.012_bib1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1365-2141.1997.d01-2095.x","article-title":"Multidrug resistance in leukemia","volume":"96","author":"McKenna","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.12.012_bib2","first-page":"48","article-title":"Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma","volume":"34","author":"Valkov","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2008.12.012_bib3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrm831","article-title":"Cellular role of DNA topoisomerases: a molecular perspective","volume":"3","author":"Wang","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.leukres.2008.12.012_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/379225a0","article-title":"Structure and mechanism of DNA topoisomerase II","volume":"379","author":"Berger","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2008.12.012_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(02)00715-5","article-title":"Culprit and victim\u2014DNA topoisomerase II","volume":"3","author":"Kellner","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2008.12.012_bib6","first-page":"1498","article-title":"Topoisomerase II \u03b1 expression in acute myeloid leukaemia and its relationship to clinical outcome","volume":"8","author":"McKenna","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.12.012_bib7","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2141.1995.tb03312.x","article-title":"Expression of mdr1, mrp, topoisomerase II\u03b1\/\u03b2, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias","volume":"89","author":"Beck","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.12.012_bib8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1046\/j.1365-2141.1998.00713.x","article-title":"Evidence for a critical role of DNA topoisomerase II\u03b1 in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line","volume":"101","author":"Towatari","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.12.012_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev.bi.58.070189.002031","article-title":"DNA topoisomerase poisons as antitumor drugs","volume":"58","author":"Liu","year":"1989","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.leukres.2008.12.012_bib10","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1073\/pnas.85.4.1086","article-title":"Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle","volume":"85","author":"Heck","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2008.12.012_bib11","first-page":"209","article-title":"Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells","volume":"2","author":"Woessner","year":"1991","journal-title":"Cell Growth Differ"},{"key":"10.1016\/j.leukres.2008.12.012_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0167-4781(98)00131-6","article-title":"Physiological regulation of eukaryotic topoisomerase II","volume":"1400","author":"Isaacs","year":"1998","journal-title":"Bio et Biophysica Acta"},{"key":"10.1016\/j.leukres.2008.12.012_bib13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V83.2.517.517","article-title":"Topoisomerase II level and drug sensitivity in adult acute myelogenous leukemia","volume":"83","author":"Kaufmann","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.12.012_bib14","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood.V86.10.3861.bloodjournal86103861","article-title":"In vitro cellular drug resistance in children with relapsed\/refractory acute lymphoblastic leukemia","volume":"86","author":"Klumper","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.12.012_bib15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0145-2126(01)00184-9","article-title":"Potential mechanisms of resistance to cytarabine in AML patients","volume":"26","author":"Galmarini","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.12.012_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-3835(97)04742-3","article-title":"Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines","volume":"116","author":"Satake","year":"1997","journal-title":"Cancer Lett"},{"key":"10.1016\/j.leukres.2008.12.012_bib17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","article-title":"Proposals for the classification of acute myeloid leukemia. A report of the French\u2013American\u2013British Cooperative Group","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.leukres.2008.12.012_bib18","first-page":"200","article-title":"Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan adult leukemia study group (JALSG): results of an interim analysis","volume":"72","author":"Okamoto","year":"2000","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2008.12.012_bib19","first-page":"97","article-title":"No beneficial effect from addition of etoposide to daunorubicin, cytarabin, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group","volume":"70","author":"Miyawaki","year":"1999","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2008.12.012_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2000.2000","article-title":"Randomized clinical trial of induction therapy comparing intensified daunorubicin with idarubicin in patients with previously untreated de novo acute myeloid leukemia (JALSG AML201 Study)","volume":"108","author":"Ohtake","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.12.012_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2006-08-043992","article-title":"A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RAR\u03b1 transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study","volume":"110","author":"Asou","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.12.012_bib22","first-page":"298a","article-title":"Randomized clinical trial of response-oriented individualized versus fixed schedule induction chemotherapy in adult acute myeloid leukemia: the JALSG AML95 Study","volume":"10","author":"Ohtake","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.12.012_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.1986.4.1.57","article-title":"Lymphoblastic lymphoma in adults","volume":"4","author":"Slater","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2008.12.012_bib24","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2004-04-1389","article-title":"Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia","volume":"104","author":"Towatari","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.12.012_bib25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495","article-title":"Improved outcome in adult B-cell acute lymphoblastic leukemia","volume":"87","author":"Hoelzer","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.12.012_bib26","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/sj.leu.2402526","article-title":"Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study","volume":"16","author":"Takeuchi","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.12.012_bib27","first-page":"505","article-title":"Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial","volume":"84","author":"Martino","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.12.012_bib28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.leukres.2006.10.012","article-title":"Multidrug resistance protein expression of adult T-cell leukemia\/lymphoma","volume":"31","author":"Yasunami","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.12.012_bib29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0145-2126(01)00144-8","article-title":"Real-time RT-PCR for the determination of topoisomerase II mRNA level in leukaemic cells","volume":"26","author":"Zhou","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.12.012_bib30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1600-0609.1997.tb00946.x","article-title":"Recovery of drug sensitivity by MS-209, a new multidrug resistance-reversing agent, on acute myelogenous leukaemic blasts and K562 cells resistant to adriamycin cell line","volume":"58","author":"Wang","year":"1997","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2008.12.012_bib31","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V91.9.3163","article-title":"Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides","volume":"91","author":"Motomura","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.12.012_bib32","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.leu.2401117","article-title":"Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques","volume":"12","author":"Legrand","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.12.012_bib33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/cyto.990080209","article-title":"Experimental parameters and a biological standard for acridine orange detection of drug-induced alterations in chromatin condensation","volume":"8","author":"Block","year":"1987","journal-title":"Cytometry"},{"key":"10.1016\/j.leukres.2008.12.012_bib34","first-page":"S39","article-title":"MDR1, MRP, topoisomerase II\u03b1\/\u03b2, and cyclin A gene expression in acute and chronic leukemias","volume":"Suppl. 3","author":"Beck","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.12.012_bib35","first-page":"426","article-title":"Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML","volume":"10","author":"Beck","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.12.012_bib36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/bjc.1992.304","article-title":"Mdr1\/P-glycoprotein, topoisomerase, and glutathione-S-transferase \u03c0 gene expression in primary and relapsed state adult and childhood leukaemias","volume":"66","author":"Gekeler","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2008.12.012_bib37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-0609.1997.tb00979.x","article-title":"Five putative drug resistance parameters (MDR1\/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase II\u03b1) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK)","volume":"59","author":"Lohri","year":"1997","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2008.12.012_bib38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.leukres.2003.09.009","article-title":"Impact of topoisomerase II alpha and spermine on the clinical outcome of children with acute lymphoblastic leukemia","volume":"28","author":"Grandgirard","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.12.012_bib39","first-page":"6592","article-title":"Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines","volume":"51","author":"Fry","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2008.12.012_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jnci\/84.2.113","article-title":"Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines","volume":"84","author":"Kasahara","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2008.12.012_bib41","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/carcin\/14.9.1841","article-title":"Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair","volume":"14","author":"Stevnsner","year":"1993","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.leukres.2008.12.012_bib42","first-page":"1997","article-title":"Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma. A multivariate study","volume":"150","author":"Rudolph","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.leukres.2008.12.012_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/(SICI)1096-9896(199901)187:2<207::AID-PATH223>3.0.CO;2-U","article-title":"Correlation between p53, c-erbB-2, and topoisomerase II\u03b1 expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications","volume":"187","author":"Rudolph","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.leukres.2008.12.012_bib44","first-page":"1653","article-title":"Topoisomerase II\u03b1 gene expression in childhood acute lymphoblastic leukemia","volume":"9","author":"Klumper","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.12.012_bib45","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0145-2126(01)00062-5","article-title":"Expression of topoisomerase II\u03b1 in the G0\/G1 cell cycle phase of fresh leukemic cells","volume":"25","author":"Uggla","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.12.012_bib46","series-title":"Frontiers in cancer research","article-title":"Clinical significance of P-glycoprotein in acute leukemia and a strategy to overcome drug resistance","author":"Motoji","year":"2006"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608005626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608005626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T07:05:21Z","timestamp":1589526321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212608005626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0145212608005626"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.12.012","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}